Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,376.46 113.90 0.70%
S&P 500 1,853.26 10.28 0.56%
NASDAQ 4,061.96 27.80 0.69%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Nanosphere Announces Second Quarter Results, Revises 2013 Guidance and Affirms Timing of Pipeline Products


Nanosphere Announces Second Quarter Results, Revises 2013 Guidance and Affirms Timing of Pipeline Products

NORTHBROOK, IL -- (Marketwired) -- 08/06/13 -- Nanosphere, Inc. (NASDAQ: NSPH)


 
--  Q2 2013 produced revenues of $1.9 million and 35 new customer
    placements
--  2013 guidance revised to $10-11 million in revenue and 150-200
    customer placements
--  Gram-negative blood stream infection panel and enteric panel set for
    submission to the FDA in Q3 and Q4 2013, respectively

Nanosphere, Inc., a company enhancing medicine through targeted molecular diagnostics, today reported financial results for the second quarter ended June 30, 2013.

Operational Results and Business Guidance

Second quarter revenue was $1.9 million, compared to $1.3 million in the second quarter of 2012. The 38% year-over-year growth was driven primarily by sales of the company's FDA-cleared Verigene(R) Gram-Positive Blood Culture Test. Nanosphere is revising its 2013 revenue guidance of $13-15 million down to $10-11 million.

The Company achieved 35 new customer placements in the second quarter of 2013. This year's placement guidance of 200-250 is revised to 150-200.

Michael McGarrity, President and Chief Executive Officer of Nanosphere, commented:

"We are lowering 2013 revenue and placement guidance to better reflect the extensive implementation process that our customers utilize in validating our Gram-Positive Blood Culture test as they adopt this significant change in diagnostic protocol. We are encouraged by the following indicators that confirm we are building a footprint and foundation for a sustainable revenue ramp:


 
--  our customers are generating clinically actionable results throughout
    the validation and implementation process;
--  the data generated and published by these customers confirms the
    accuracy and performance of our tests in earlier disease detection,
    optimal patient treatment and improved healthcare economics for one of
    the most complex, costly and deadly disease states; and
--  our investment in and focus on streamlining the implementation process
    will serve to accelerate our revenue growth in the coming quarters."

Mr. McGarrity continued, "We expect this momentum to be further bolstered by our gram-negative and gastrointestinal enteric menu additions, each on track for submission to the FDA in 2013."

Costs of product sales increased to $1.3 million in the second quarter of 2013 from $0.9 million in the second quarter of 2012 due to increased volume.

Research and development expenses in the second quarter of 2013 decreased to $3.1 million from $4.7 million in the same period of 2012. The decrease was driven by reduced spending on development goods and materials, and the capitalization of raw material inventory that was previously expensed.

Selling, general and administrative expenses in the second quarter of 2013 increased to $5.1 million from $4.2 million in the second quarter of 2012. This was due to expansion of the field sales and customer support teams, as well as clinical trial expenses supporting the Company's expanding pipeline.

Net loss for the second quarter of 2013 was $7.8 million, compared with $8.4 million in the second quarter of 2012.

Cash flow for the second quarter of 2013 was positive $7.6 million including a $16.5 million increase from financing activities and $8.8 million decrease from operating activities. Cash at June 30, 2013 was $32.0 million.

Conference Call and Webcast Details

Tuesday, August 6, 2013 at 5:00 P.M., Eastern Time Domestic: 888-713-4205 International: 617-213-4862 Passcode: 74181181

Webcast: http://www.nanosphere.us/page/investor-overview

Replay: Available through August 14, 2013 on the Company's website or by dialing: Domestic: 888-286-8010 International: 617-801-6888

Passcode: 27570830

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene(R) System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


 
                                                                            
                                                                            
                              Nanosphere, Inc.                              
                          Statements of Operations                          
          (dollars and shares in thousands except per share data)           
                                (Unaudited)                                 
                                                                            
                                                      Three Month Periods   
                                                        Ended June 30,      
                                                       2013         2012    
                                                   -----------  ----------- 
                                                                            
                                                                            
REVENUE:                                                                    
  Product sales                                    $     1,852  $     1,315 
  Grant and contract revenue                                 -           30 
                                                   -----------  ----------- 
    Total revenue                                        1,852        1,345 
COSTS AND EXPENSES:                                                         
  Cost of sales                                          1,269          884 
  Research and development                               3,092        4,716 
  Sales, general, and administrative                     5,129        4,196 
                                                   -----------  ----------- 
    Total costs and expenses                             9,490        9,796 
                                                   -----------  ----------- 
    Loss from operations                                (7,638)      (8,451)
OTHER INCOME (EXPENSE):                                                     
  Foreign exchange gain (loss)                              (1)          (1)
  Interest expense                                        (213)           - 
  Interest income                                            5           13 
                                                   -----------  ----------- 
    Total other income (expense)                          (209)          12 
                                                   -----------  ----------- 
NET LOSS                                           $    (7,847) $    (8,439)
                                                   ===========  =========== 
                                                                            
Net loss per common share - basic and diluted      $     (0.14) $     (0.19)
Weighted average number of common shares                                    
 outstanding - basic and diluted                        56,998       43,716 
                                                                            
                                                                            
                                                                            
                                                                            
                              Nanosphere, Inc.                              
                          Condensed Balance Sheets                          
                           (dollars in thousands)                           
                                 (Unaudited)                                
                                                                            
                                                      June 30,  December 31,
                                                        2013        2012    
                                                    ----------- ------------
                                                                            
                                                                            
Cash and cash equivalents                           $    31,963 $     33,139
Other current assets                                     10,097        8,637
                                                    ----------- ------------
Total current assets                                     42,060       41,776
Net property and equipment                                3,278        2,872
Intangible assets - net of accumulated                                      
 amortization.                                            2,571        2,733
Other assets                                                337           76
                                                    ----------- ------------
Total assets                                        $    48,246 $     47,457
                                                    =========== ============
                                                                            
Total liabilities                     
              $    16,451 $      5,225
Total stockholders' equity                               31,795       42,232
                                                    ----------- ------------
Total liabilities and stockholders' equity          $    48,246 $     47,457
                                                    =========== ============

Contacts

Investors: Roger Moody Chief Financial Officer Nanosphere, Inc. 847-400-9021 rmoody@nanosphere.us

Michael Rice Founding Partner LifeSci Advisors 646-597-6979 mrice@lifesciadvisors.com

Media: Lindsey Saxon Director of Communications Nanosphere, Inc. 847-400-9173 lsaxon@nanosphere.us

Geoff Curtis Edelman 312-233-1253 geoff.curtis@edelman.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement